Imunon, Inc.

Healthcare · Biotechnology · United States

Last price 0.91 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 5.11M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develo...